Email a Friend
Print ArticleHealthy Aging Health Center
Healthy Aging - References
Citations
Colcombe SJ, et al. (2003). Aerobic fitness reduces brain tissue loss in aging humans. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 58: M176–M180.
U.S. Department of Health and Human Services (2008). 2008 Physical Activity Guidelines for Americans (ODPHP Publication No. U0036). Washington, DC: U.S. Government Printing Office. Available online: http://www.health.gov/paguidelines/pdf/paguide.pdf.
Duke J, et al. (2002). Giving up and replacing activities in response to illness. Journal of Gerontology, 57B(4): P367–P376.
Yaffe K, et al. (2001). A prospective study of physical activity and cognitive decline in elderly women. Archives of Internal Medicine, 161: 1703–1708.
Larson EB, et al. (2006). Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine, 144(2): 73–81.
Cacioppo JT, et al. (2002). Loneliness and health: Potential mechanisms. Psychosomatic Medicine, 64: 407–417.
Morrow-Howell N, et al. (2003). Effects of volunteering on the well-being of older adults. Journal of Gerontology, 58B(3): S137–S145.
Ott A, et al. (2004). Effect of smoking on global cognitive function in nondemented elderly. Neurology, 62: 920–924.
Other Works Consulted
Johnson LE, Alline KM (2007). Sexual health. In RJ Ham et al., eds., Primary Care Geriatrics, 5th ed., pp. 401–407. Philadelphia: Mosby Elsevier.
Barker WH (2008). Prevention of disability in older persons. In RB Wallace et al., eds., Wallace/Maxcy-Rosenau-Last Public Health and Preventive Medicine, 15th ed., pp. 1185–1194. New York: McGraw-Hill.
National Osteoporosis Foundation (2008). Clinician's Guide to Prevention and Treatment of Osteoporosis. Available online: http://www.nof.org/professionals/Clinicians_Guide.htm.
Palmer RM (2004). Management of common clinical disorders in geriatric patients. In DC Dale, DD Federman, eds., ACP Medicine, section 8, chap. 9. New York: WebMD.
WebMD Medical Reference from Healthwise
Healthy Aging Topics
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.
